. 2009 Jun 30;114(10):2037–2043. doi: 10.1182/blood-2009-01-197715

Table 5.

Multivariate analysis

Positive features	MCyR		EFS		OS
Positive features	Odds ratio	P	Hazard ratio	P	Hazard ratio	P
Chronic phase	0.29	< .001	2.2	< .001	4.2	< .001
No or low IC₅₀ mutation	0.18	.003	2.1	.002	1.8	.06
Previous MCyR to imatinib	7.5	< .001	0.56	.006	0.56	.04